Vaccine makers tap into virus-driven rally to raise money – MarketWatch

Some small vaccine developers that saw their stocks take off on Tuesday over growing concern about the brand-new coronavirus are utilizing the

rally to raise money.

Read:

This is how far and quickly the coronavirus has spread out through U.S.

” We don’t anticipate Novavax will run human trials without non-dilutive federal government funding,” Ladenburg Thalmann’s Michael Higgens composed in a note. “The timing for such support in our view depends upon how extreme and unchecked the 2019-nCoV becomes.”

Novavax Inc. NVAX, -27.80 %in 2013 established a vaccine for Middle East respiratory syndrome (MERS), which is likewise a coronavirus. On Tuesday after the market closed, the business filed a shelf registration looking for to raise more than $100 million gradually. A spokesperson said Novavax also prepares to develop a vaccine for the coronavirus. Its stock fell 15 %in early trade Wednesday on issues about dilution.

stocks Moderna Inc.

< period class=" quote up bgQuote" data-channel="

NanoViricides Inc.

/ zigman2/quotes/205619834/ composite “data-bgformat=” “> MRNA, +4.92% stated it is dealing with the National Institutes of Health on a potential vaccine reaction, stating its “vaccine innovation could function as a flexible and rapid platform that might work in reacting to newly emerging viral dangers.” Moderna’s stock was up 10%. < span class=" quote down bgQuote" data-channel="

/ zigman2/quotes/202808333/ composite” data-bgformat=”” > NNVC, -55.06% stated it has raised $ 7.5 million in an offering of 2.5 million shares at a cost of $ 3 per share.

Its stock was down 55% in early morning trading, after getting 153% on Monday. The company had actually likewise dealt with treatments for MERS and the Ebola infection. NanoViricides president Anil Diwan stated in an email that the business believes that the drugs “we had actually previously developed are worth screening versus the Wuhan infection and are likely to work against it.”

” Some equities thought to have a potential tie to treatment or prevention of this contagious illness have actually seen favorable movement today, however we believe that movement is overblown,” composed Raymond James’ Chris Meekins on Tuesday.

The infection was initially identified in December in Wuhan City, China. It has considering that sickened more than 300 individuals, consisting of a U.S. local who had traveled to Wuhan this month, according to the Centers for Disease Control and Prevention. China’s National Health Commission

informed news outlets that nine people have passed away and at least 440 individuals in China have been contaminated. Health officials now think the infection is spread human to human.

The SPDR S&P Biotech

/ zigman2/quotes/205950134/ composite” data-bgformat =”” > XBI, -0.23% exchange-traded fund has climbed up 13% over the in 2015, while the S&P 500

< period class=" quote down bgQuote" data-channel="

SPX, +0.03 % has gained 26 %.

Novavax Inc. NVAX, -27.80 %in 2013 developed a vaccine for Middle East respiratory syndrome (MERS), which is also a coronavirus. A representative stated Novavax also plans to establish a vaccine for the coronavirus. Its stock was down 55% in morning trading, after getting 153% on Monday. The company had actually also worked on treatments for MERS and the Ebola virus.

from WordPress http://troot.net/vaccine-makers-tap-into-virus-driven-rally-to-raise-money-marketwatch/